Celularity Inc. (CELU )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CELU
- Company Celularity Inc.
- Price $1.85
- Changes Percentage 17.09
- Change 0.27
- Day Low $1.38
- Day High $1.96
- Year High $4.01
- Year Low $0.56
- Market Cap $23,156,800
- Price Avg 50 EMA (D) $0.72
- Price Avg 200 EMA (D) $1.15
- Exchange NASDAQ
- Volume 26,054
- Average Volume 103,335
- Open $1.42
- Previous Close $1.58
- EPS -3.6
- PE -0.22
- Earnings Announcement 2026-08-21 12:00:00
- Shares Outstanding $28,946,000
Company brief: CELULARITY INC. (CELU )
- Healthcare
- Biotechnology
- Dr. Robert Joseph Hariri M.D., Ph.D.
- https://www.celularity.com
- US
- N/A
- 08-08-2019
- US1511902041
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.